Catalog
See full images - free registration
Continue with Google - no registration!
or register with email
Why register? Just to keep bots out of our catalog. Your email stays private - we will never share it or send you anything uninvited. We guarantee you that!
100 Francs - Ahmad II Obverse Essai
| Issuer | Monnaie de Paris |
|---|---|
| Year | 1930 |
| Type | Coin pattern |
| Value | Log in to see details |
| Currency | Log in to see details |
| Composition | Log in to see details |
| Weight | Log in to see details |
| Diameter | Log in to see details |
| Thickness | Log in to see details |
| Shape | Log in to see details |
| Technique | Log in to see details |
| Orientation | Log in to see details |
| Engraver(s) | Log in to see details |
| In circulation to | Log in to see details |
| Reference(s) | Log in to see details |
| Obverse description | Log in to see details |
|---|---|
| Obverse script | Arabic |
| Obverse lettering | Log in to see details |
| Reverse description | Entirely blank field bearing multiple concentric lathe-turned die lines radiating from the centre, a characteristic feature of obverse-only essai pieces produced at the Monnaie de Paris. The surface shows the tool marks of the die-turning process without any decorative or inscriptional elements, confirming this piece was struck solely to test the obverse die. |
| Reverse script | Log in to see details |
| Reverse lettering | Log in to see details |
| Edge | Log in to see details |
| Mint | Log in to see details |
| Mintage | Log in to see details |
| Additional information |
Essais of the French Protectorate Tunisian coinage were struck at Paris as trial pieces for approval before circulation dies were committed — Ahmad II Bey, who ruled Tunisia from 1929 until his death in 1942, was nominally sovereign while France controlled all administrative and monetary decisions. The gilt bronze composition here is characteristic of the less prestigious tier of essai striking; a full gold version in the same design was also produced, making this the more accessible of the two parallel trial types.